Highlights of the 2026 European Crohn’s and Colitis Conference: Redefining the IBD Care Continuum
Clicks: 1
ID: 320190
2026
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
0.0
/100
1 views
0 readers
AI Quality Assessment
Not analyzed
Readership in this journal
Ranked #36 of 38 articles by views in Crohn s & Colitis 360
Most read
Least read
Bar heights use a square-root scale.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
Abstract Introduction and Purpose Inflammatory bowel disease care is moving from a symptom-driven step-up model of care toward earlier effective intervention, complication-specific management, and more personalized treatment selection. This review synthesizes selected ECCO 2026 studies and offers an expert appraisal of their clinical relevance, methodological strengths, and remaining uncertainties. Particular emphasis is placed on studies most likely to influence current practice and further research, including late-breaking trials, complication-directed therapy, pediatric evidence, and technology-assisted assessment. Summary of Findings Study findings spanned both ulcerative colitis and Crohn’s disease. New therapeutic studies presented included the phase 3 study of vedolizumab in pediatric ulcerative colitis (UC), phase 2 efficacy data for picankibart in UC, and regenerative fistula data of AVB-114 in perianal Crohn’s disease (CD). Real-world data presented included comparative data of different JAKi in UC. Updates on IL-23 included durable extension data in UC, as well as efficacy data in advanced therapy‑exposed patients (mirikizumab in UC and risankizumab in CD). Innovative technologies included transperineal ultrasound for early identification of steroid non-response in acute severe ulcerative colitis, and multimodal artificial intelligence for Mayo endoscopic scoring. Beyond drug therapy, the 10-year LIR! C follow-up provided further data on surgical intervention as an early strategy in selected uncomplicated ileal CD, while the PIONIR study investigated potential benefits of a whole-food diet in high-risk first-degree relatives. Conclusion and Next Steps ECCO 2026 emphasized durable, precision-oriented, multidisciplinary, and technology-enabled inflammatory bowel disease care across the full continuum, from prevention to long-term modification. Apart from phase 3 and extension trials, other results remain preliminary and need broader comparative and practice-embedded studies before widespread adoption.
| Reference Key |
openalex_W7167578125
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | Ahmed Al-Hindawi, Alexander Siegel, Clive J. Miranda, Gautam Maddineni, Mohammad Shehab |
| Journal | Crohn s & Colitis 360 |
| Year | 2026 |
| DOI |
10.1093/crocol/otag075
|
| URL | |
| Keywords | Keywords not found |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.